Functional Diarrhea

Gastroenterology Clinics of North America

Volumn 41, Issue 3, 2012, Pages 629-637

  Tack, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Chronic diarrhea; Functional diarrhea; Irritable bowel syndrome; Rapid intestinal transit

Indexed keywords

ACETORPHAN; ALOSETRON; AMITRIPTYLINE; ATROPINE; BISMUTH SALICYLATE; CLONIDINE; CODEINE; COLESTYRAMINE; DESIPRAMINE; DIPHENOXYLATE; ISPAGULA; LIDAMIDINE; LOPERAMIDE; OCTREOTIDE; OPIATE AGONIST; PLACEBO; PROBIOTIC AGENT; SEROTONIN 3 ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT;

CHRONIC DIARRHEA; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENTERITIS; FECES INCONTINENCE; FUNCTIONAL DIARRHEA; GALLSTONE; HUMAN; HYPOTENSION; INTESTINE TRANSIT TIME; LACTOBACILLUS ACIDOPHILUS; MORNING DOSAGE; NAUSEA; NUTRITIONAL INTOLERANCE; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIDIARRHEALS; BISMUTH; CARBON; CHOLESTYRAMINE RESIN; CHRONIC DISEASE; CLONIDINE; DIARRHEA; HUMANS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; OXIDES; PROBIOTICS; RECEPTORS, OPIOID; SALICYLATES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; THIORPHAN;

EID: 84865374097     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.06.007     Document Type: Review

References (61)

1. Fine K.D., Schiller L.R. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999, 116:1464-1486.
2. Schiller L.R. Chronic diarrhea. Gastroenterology 2004, 127:287-293.
3. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130(5):1480-1491.
4. Sandler R.S., Drossman D.A. Bowel habits in young adults not seeking health care. Dig Dis Sci 1987, 32:841-845.
5. Lewis S.J., Heaton K.W. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997, 32(9):920-924.
6. Sandler R.S., Stewart W.F., Liberman J.N., et al. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci 2000, 45(6):1166-1171.
7. Chang J.Y., Locke G.R., Schleck C.D., et al. Risk factors for chronic diarrhoea in the community in the absence of irritable bowel syndrome. Neurogastroenterol Motil 2009, 21(10):1060-e87.
8. Camilleri M. Chronic diarrhea: a review on pathophysiology and management for the clinical gastroenterologist. Clin Gastroenterol Hepatol 2004, 2(3):198-206.
9. Spiller R.C., Thompson W.G. Bowel disorders. Am J Gastroenterol 2010, 105(4):775-785.
10. Bazzocchi G., Ellis J., Villanueva-Meyer J., et al. Effect of eating on colonic motility and transit in patients with functional diarrhea. Gastroenterology 1991, 101:1298-1306.
11. Cann P.A., Read N.W., Cammack J., et al. Psychological stress and the passage of a standard meal through the stomach and small intestine in man. Gut 1983, 24:236-240.
12. Spiller R.C. Inflammation as a basis for functional GI disorders. Best Pract Res Clin Gastroenterol 2004, 18(4):641-661.
13. Lomer M.C., Parkes G.C., Sanderson J.D. Review article: lactose intolerance in clinical practice-myths and realities. Aliment Pharmacol Ther 2008, 27(2):93-103.
14. Parker T.J., Naylor S.J., Riordan A.M., et al. Management of patients with food intolerance in irritable bowel syndrome: the development and use of an exclusion diet. J Hum Nutr Diet 1995, 8:159-166.
15. Lavo B., Stenstam M., Nielsen A.L. Loperamide in treatment of irritable bowel syndrome-a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987, 22:77-80.
16. Corazziari E. Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol 1999, 13(Suppl A):71A-75A.
17. Read M., Read N.W., Barber D.C., et al. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhoea with faecal incontinence and urgency. Dig Dis Sci 1982, 27:807-814.
18. Sun W.M., Read N.W., Verlinden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol 1997, 32:34-38.
19. Gattuso J.M., Kamm M.A. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Saf 1994, 10:47-65.
20. Harford W.V., Krejs G.J., Santa Ana C.A., et al. Acute effect of diphenoxylate with atropine (Lomotil) in patients with chronic diarrhoea and faecal incontinence. Gastroenterology 1980, 78:440-443.
21. Palmer K.R., Corbett C.L., Holdsworth C.D. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhoea. Gastroenterology 1980, 79:1272-1275.
22. Allison M.C., Sercombe J., Pounder R.E. A double-blind crossover comparison of lidamidine, loperamide and placebo for the control of chronic diarrhoea. Aliment Pharmacol Ther 1988, 2:347-351.
23. Talley N.J., Phillips S.F., Haddad A., et al. Effect of selective 5HT3 antagonist (GR38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci 1989, 34:1511-1515.
24. Thumshirn M., Coulie B., Camilleri M., et al. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000, 14(7):869-878.
25. Camilleri M., Northcutt A.R., Kong S.A., et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000, 355:1035-1040.
26. Lembo A.J., Olden K.W., Ameen V.Z., et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2004, 2:675-682.
27. Thompson C.A. Alosetron withdrawn from market. Am J Health Syst Pharm 2001, 58:13.
28. Chang L., Tong K., Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol 2010, 105(4):866-875.
29. Matsueda K., Harasawa S., Hongo M., et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008, 77(3-4):225-235.
30. Lee K.J., Kim N.Y., Kwon J.K., et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011, 23(12):1098-1104.
31. Santoro G.A., Eitan B.Z., Pryde A., et al. Open study of low dose amitriptyline in the treatment of patients with idiopathic fecal incontinence. Dis Colon Rectum 2000, 43:1676-1682.
32. Drossman D.A., Toner B.B., Whitehead W.E., et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003, 125:19-31.
33. Prado D. A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand J Gastroenterol 2002, 37:656-661. Global Adult Racecadotril Study Group.
34. Gallelli L., Colosimo M., Tolotta G.A., et al. Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. Eur J Clin Pharmacol 2010, 66(2):137-144.
35. Bergmann J.F., Chaussade S., Couturier D., et al. Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers. Aliment Pharmacol Ther 1992, 6(3):305-313.
36. Sciarretta G., Vicini G., Fagioli G., et al. Use of 23-selena-25-homocholyltaurine to detect bile acid malabsorption in patients with ileal dysfunction or diarrhea. Gastroenterology 1986, 91:1-9.
37. Sciarretta G., Fagioli G., Furno A., et al. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut 1987, 28:970-975.
38. Suhr O., Danielsson A., Nyhlin H., et al. Bile acid malabsorption demonstrated by SeHCAT in chronic diarrhoea, with special reference to the impact of cholecystectomy. Scand J Gastroenterol 1988, 23:1187-1194.
39. Williams A.J., Merrick M.V., Eastwood M.A. Idiopathic bile acid malabsorption-a review of clinical presentation, diagnosis, and response to treatment. Gut 1991, 32:1004-1006.
40. Eusufzai S. Bile acid malabsorption in patients with chronic diarrhoea. Scand J Gastroenterol 1993, 28:865-868.
41. Rudberg U., Nylander B. Radiological bile acid absorption test 75SeHCAT in patients with diarrhoea of unknown cause. Acta Radiol 1996, 37:672-675.
42. Niaz S.K., Sandrasegaran K., Renny F.H., et al. Postinfective diarrhoea and bile acid malabsorption. J R Coll Physicians Lond 1997, 31:53-56.
43. Wildt S., Norby Rasmussen S., Lysgard Madsen J., et al. Bile acid malabsorption in patients with chronic diarrhoea: clinical value of SeHCAT test. Scand J Gastroenterol 2003, 38:826-830.
44. Duncombe V.M., Bolin T.D., Davis A.E. Double-blind trial of cholestyramine in post-vagotomy diarrhoea. Gut 1977, 18:531-535.
45. Sinha L., Liston R., Testa H.J., et al. Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther 1998, 12:839-844.
46. Fine K.D., Lee E.L. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology 1998, 114:29-36.
47. Fine K.D., Ogunji F., Lee E. Randomized, double-blind, placebo controlled trial of bismuth subsalicylate for microscopic colitis. Gastroenterology 1999, 116:A880. [abstract].
48. Chassagne P., Jego A., Gloc P., et al. Does treatment of constipation improve faecal incontinence in institutionalized elderly patients?. Age Ageing 2000, 29:159-164.
49. Bliss D.Z., Jung H.J., Savik K., et al. Supplementation with dietary fiber improves fecal incontinence. Nurs Res 2001, 50:203-213.
50. Qvitzau S., Matzen P., Madsen P. Treatment of chronic diarrhoea: loperamide versus ispaghula husk and calcium. Scand J Gastroenterol 1988, 23:1237-1240.
51. Tack J.F., Miner P.B., Fischer L., et al. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011, 34(8):868-877.
52. Xiao S.D., Zhang D.Z., Lu H., et al. Multicenter, randomized, controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhea. Adv Ther 2003, 20:253-260.
53. Fedorak R.N., Field M., Chang E.B. Treatment of diabetic diarrhea with clonidine. Ann Intern Med 1985, 102:197-199.
54. Rubinoff M.J., Piccione P.R., Holt P.R. Clonidine prolongs human small intestine transit time: use of the lactulose-breath hydrogen test. Am J Gastroenterol 1989, 84:372-374.
55. Viramontes B.E., Malcolm A., Camilleri M., et al. Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol 2001, 281:G1468-G1476.
56. Farthing M.J. Octreotide in the treatment of refractory diarrhoea and intestinal fistulae. Gut 1994, 35(Suppl 3):S5-S10.
57. Valdovinos M.A., Camilleri M., Zimmerman B.R. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc 1993, 68:691-702.
58. Fried M. Octreotide in the treatment of refractory diarrhea. Digestion 1999, 60(Suppl 2):42-46.
59. Redfern J.S., Fortuner W.J. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol 1995, 90:1042-1052.
60. Rosenoff S. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Support Care Cancer 2004, 12:561-570.
61. Ricci S., Antonuzzo A., Galli L., et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000, 11:1127-1130.